Semaglutide product description — GLP-1 receptor agonist peptide
Research Peptide · GLP-1 Agonist
Semaglutide
A synthetic peptide engineered to resist rapid enzymatic breakdown, enabling once-weekly subcutaneous dosing or once-daily oral administration. Purity >99% · Double lab tested.
Brand names
Ozempic
Type 2 diabetes · Approved 2017
Injectable
Rybelsus
Type 2 diabetes · Approved 2019
Oral
Wegovy
Weight management · Approved 2021
Injectable
Approved indications
- Glycemic control in type 2 diabetes
- Cardiovascular risk reduction
- Chronic weight management
- Kidney disease progression (T2D)
- Non-cirrhotic MASH (Wegovy)
Mechanism of action
Insulin stimulation
Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, keeping hypoglycemia risk low during monotherapy.
Stimulates pancreatic beta cells to release insulin in response to elevated blood glucose, keeping hypoglycemia risk low during monotherapy.
Glucagon suppression
Suppresses inappropriate glucagon release from alpha cells, reducing hepatic glucose output.
Suppresses inappropriate glucagon release from alpha cells, reducing hepatic glucose output.
Gastric emptying
Slows the rate at which the stomach empties, prolonging fullness after meals.
Slows the rate at which the stomach empties, prolonging fullness after meals.
Appetite regulation
Acts on hypothalamus and brainstem receptors to reduce hunger and the rewarding qualities of palatable food.
Acts on hypothalamus and brainstem receptors to reduce hunger and the rewarding qualities of palatable food.
Key clinical trials
STEP 1 — Weight management
Adults with obesity received 2.4 mg semaglutide weekly for 68 weeks vs. placebo.
~14.9% weight loss (treatment)
~2.4% (placebo)
~2.4% (placebo)
SELECT — Cardiovascular
Demonstrated reduced risk of major adverse cardiovascular events in adults with overweight/obesity and established CVD without diabetes.
SUSTAIN & FLOW
SUSTAIN established glycemic efficacy in type 2 diabetes. FLOW supported the kidney disease indication.
Adverse effects & safety
Most common effects are gastrointestinal and dose-dependent: nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
- Pancreatitis and gallbladder disease
- Acute kidney injury (often linked to GI-related dehydration)
- Diabetic retinopathy complications
- Elevated hypoglycemia risk when combined with insulin or sulfonylureas
Boxed warning: risk of thyroid C-cell tumors based on rodent studies. Contraindicated in patients with medullary thyroid carcinoma history or MEN-2. Also contraindicated in pregnancy.




Reviews
There are no reviews yet.